Portopulmonary Hypertension

被引：4

作者：

Al-Naamani, Nadine ^{[1
]}

Roberts, Kari E. ^{[1
]}

机构：

[1] Tufts Med Ctr, Boston, MA 02111 USA

来源：

CLINICS IN CHEST MEDICINE | 2013年 / 34卷 / 04期

关键词：

Hypertension; portal; pulmonary; Liver transplantation; PULMONARY ARTERIAL-HYPERTENSION; LIVER-TRANSPLANT CANDIDATES; HYPERDYNAMIC SPLANCHNIC CIRCULATION; COMPLICATING PORTAL-HYPERTENSION; CALCIUM-CHANNEL BLOCKERS; LONG-TERM RESPONSE; HEPATOPULMONARY SYNDROME; INHALED ILOPROST; ARTERIOVENOUS-MALFORMATIONS; ORAL SILDENAFIL;

D O I：

10.1016/j.ccm.2013.08.008

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Diagnosis of portopulmonary hypertension (PoPH), is challenging because of the multitude of cardiac and pulmonary diseases that cosegregate with advanced liver disease. PoPH is unique in that its natural history is not wholly dependent on portal hypertension. Despite a dearth of randomized, prospective data, an ever-expanding clinical experience shows that patients with PoPH benefit from therapy with PAH-specific medications. Because of high perioperative mortality, transplantation should be avoided in those patients who have severe PoPH that is refractory to medical therapy. This article reviews the pathophysiology and pathogenesis of PoPH and discusses approaches to diagnosis and management.

引用

页码：719 / +

页数：20

共 171 条

[1] Portopulmonary hypertension and liver transplantation: Hemodynamic consequences at reperfusion
Acosta, F
Sansano, T
Palenciano, CG
Domenech, P
Falcon, L
Robles, R
Bueno, FS
Ramirez, P
Parrilla, P
[J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (09) : 3865 - 3866
[2] AGGARWAL S, 1987, TRANSPLANT P, V19, P54
[3] The impact of treatment of portopulmonary hypertension on survival following liver transplantation
Ashfaq, M.
Chinnakotla, S.
Rogers, L.
Ausloos, K.
Saadeh, S.
Klintmalm, G. B.
Ramsay, M.
Davis, G. L.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (05) : 1258 - 1264
[4] Pulmonary hypertension after liver transplantation in patients with antecedent hepatopulmonary syndrome: A report of 2 cases and review of the literature
Aucejo, Federico
Miller, Charles
Vogt, David
Eghtesad, Bijan
Nakagawa, Shunichi
Stoller, James K.
[J]. LIVER TRANSPLANTATION, 2006, 12 (08) : 1278 - 1282
[5] Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension
Austin, Mark J.
McDougall, Neil I.
Wendon, Julia A.
Sizer, Elizabeth
Knisely, Alex S.
Rela, Mohammed
Wilson, Carol
Callender, Michael E.
O'Grady, John G.
Heneghan, Michael A.
[J]. LIVER TRANSPLANTATION, 2008, 14 (03) : 287 - 291
[6] Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry
Badesch, David B.
Raskob, Gary E.
Elliott, C. Greg
Krichman, Abby M.
Farber, Harrison W.
Frost, Adaani E.
Barst, Robyn. J.
Benza, Raymond L.
Liou, Theodore G.
Turner, Michelle
Giles, Scott
Feldkircher, Kathy
Miller, Dave P.
McGoon, Michael D.
[J]. CHEST, 2010, 137 (02) : 376 - 387
[7] Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines
Badesch, DB
Abman, SH
Ahearn, GS
Barst, RJ
McCrory, DC
Simonneau, G
McLaughlin, VV
[J]. CHEST, 2004, 126 (01) : 35S - 62S
[8] Successful Outcomes Following Living Donor Liver Transplantation for Portopulmonary Hypertension
Bandara, Mahesh
Gordon, Fredric D.
Sarwar, Akmal
Knauft, M. Elizabeth
Pomfret, Elizabeth A.
Freeman, Richard B.
Wirth, Joel A.
[J]. LIVER TRANSPLANTATION, 2010, 16 (08) : 983 - 989
[9] Diagnosis and differential assessment of pulmonary arterial hypertension
Barst, RJ
McGoon, M
Torbicki, A
Sitbon, O
Krowka, MJ
Olschewski, H
Gaine, S
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) : 40S - 47S
[10] Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
Barst, Robyn J.
Gibbs, J. Simon R.
Ghofrani, Hossein A.
Hoeper, Marius M.
McLaughlin, Vallerie V.
Rubin, Lewis J.
Sitbon, Olivier
Tapson, Victor F.
Galie, Nazzareno
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (01) : S78 - S84

← 1 2 3 4 5 6 7 8 9 10 →